ADMA Biologics Inc (NASDAQ:ADMA) Given Average Recommendation of “Buy” by Analysts

Shares of ADMA Biologics Inc (NASDAQ:ADMA) have been given an average rating of “Buy” by the nine analysts that are presently covering the company, Marketbeat Ratings reports. Nine research analysts have rated the stock with a buy rating. The average 12 month target price among analysts that have covered the stock in the last year is $11.17.

ADMA has been the subject of a number of recent analyst reports. WBB Securities upgraded shares of ADMA Biologics to a “buy” rating in a report on Thursday, April 4th. ValuEngine upgraded shares of Yelp from a “sell” rating to a “hold” rating in a report on Wednesday, April 3rd. Jefferies Financial Group initiated coverage on shares of ADMA Biologics in a report on Tuesday, June 4th. They issued a “buy” rating and a $8.00 price objective for the company. Maxim Group set a $8.00 price objective on shares of TrovaGene and gave the stock a “buy” rating in a report on Tuesday, April 2nd. Finally, HC Wainwright set a $7.00 price objective on shares of Armata Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, May 23rd.

Shares of ADMA remained flat at $$3.89 during mid-day trading on Monday. The stock had a trading volume of 554,289 shares, compared to its average volume of 691,734. The company has a debt-to-equity ratio of 5.70, a current ratio of 4.60 and a quick ratio of 2.39. The business’s 50 day moving average is $3.84. ADMA Biologics has a 12-month low of $2.08 and a 12-month high of $6.96. The stock has a market cap of $224.06 million, a PE ratio of -2.68 and a beta of 2.71.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($0.31) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.01. ADMA Biologics had a negative net margin of 370.27% and a negative return on equity of 210.69%. The company had revenue of $3.53 million during the quarter, compared to analyst estimates of $2.96 million. Analysts predict that ADMA Biologics will post -1.04 EPS for the current year.

In related news, major shareholder Life Sciences Maste Perceptive bought 4,000,000 shares of the firm’s stock in a transaction on Tuesday, May 21st. The stock was acquired at an average cost of $4.00 per share, for a total transaction of $16,000,000.00. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Adam S. Grossman bought 30,000 shares of the firm’s stock in a transaction on Friday, May 17th. The shares were bought at an average price of $4.00 per share, with a total value of $120,000.00. Following the completion of the purchase, the insider now owns 37,527 shares in the company, valued at approximately $150,108. The disclosure for this purchase can be found here. Over the last quarter, insiders have acquired 4,064,500 shares of company stock valued at $16,258,000. Company insiders own 18.80% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in ADMA. United Services Automobile Association purchased a new stake in ADMA Biologics during the 4th quarter valued at $27,000. Dimensional Fund Advisors LP purchased a new stake in ADMA Biologics during the 4th quarter valued at $34,000. Burns J W & Co. Inc. NY purchased a new stake in ADMA Biologics during the 1st quarter valued at $55,000. Rhumbline Advisers raised its stake in ADMA Biologics by 50.5% during the 4th quarter. Rhumbline Advisers now owns 23,279 shares of the biotechnology company’s stock valued at $56,000 after buying an additional 7,810 shares during the last quarter. Finally, Raymond James & Associates raised its stake in ADMA Biologics by 65.2% during the 4th quarter. Raymond James & Associates now owns 26,871 shares of the biotechnology company’s stock valued at $64,000 after buying an additional 10,610 shares during the last quarter. Institutional investors and hedge funds own 38.70% of the company’s stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.

Recommended Story: How is the LIBOR rate calculated?

Analyst Recommendations for ADMA Biologics (NASDAQ:ADMA)

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.